Innoviva (INVA) Change in Intangibles (2013 - 2014)
Innoviva posted quarterly Change in Intangibles of $25.0 million for Q3 2014, up 150.0% year-on-year from $10.0 million in Q3 2013, and down 44.44% on a QoQ basis from $45.0 million in Q2 2014.
Innoviva (INVA) has 2 years of Change in Intangibles data on file, last reported at $25.0 million in Q3 2014.
- For the quarter ending Q3 2014, Change in Intangibles rose 150.0% year-over-year to $25.0 million; the trailing twelve-month figure through Sep 2014 stood at $170.0 million (changed N/A YoY), and the FY2024 full-year result was $4.0 million, changed N/A from the prior year.
- Change in Intangibles for Q3 2014 stood at $25.0 million, down from $45.0 million in the prior quarter.
- Across five years, Change in Intangibles topped out at $55.0 million in Q1 2014 and bottomed at $10.0 million in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 68,980.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 25.00 Mn |
| Sep 30, 2014 | 25.00 Mn |
| Jun 30, 2014 | 45.00 Mn |
| Jun 30, 2014 | 45.00 Mn |
| Mar 31, 2014 | 55.00 Mn |
| Mar 31, 2014 | 55.00 Mn |
| Dec 31, 2013 | 45.00 Mn |
| Dec 31, 2013 | 45.00 Mn |
| Sep 30, 2013 | 10.00 Mn |
| Sep 30, 2013 | 10.00 Mn |
| Jun 30, 2013 | 30.00 Mn |
| Jun 30, 2013 | 30.00 Mn |